Personalis (NASDAQ:PSNL) Cut to “Hold” at Craig Hallum

Craig Hallum lowered shares of Personalis (NASDAQ:PSNL) from a buy rating to a hold rating in a research note released on Monday morning, MarketBeat reports. The firm currently has $16.25 target price on the stock.

A number of other research analysts have also weighed in on the company. Morgan Stanley raised their price objective on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Zacks Research downgraded shares of Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target on the stock. in a research report on Monday, July 20th. Finally, Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Personalis has an average rating of “Hold” and an average price target of $14.54.

Personalis Trading Down 1.0%

PSNL stock opened at $17.08 on Monday. Personalis has a 12-month low of $4.65 and a 12-month high of $18.89. The business’s 50-day moving average is $13.74 and its 200 day moving average is $9.87. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -15.67 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. As a group, equities analysts forecast that Personalis will post -1.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at $3,103,215.90. The trade was a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 415,123 shares of company stock worth $5,380,531 in the last three months. 4.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Personalis

Several hedge funds and other institutional investors have recently bought and sold shares of PSNL. California State Teachers Retirement System raised its stake in Personalis by 37,061.5% during the second quarter. California State Teachers Retirement System now owns 1,008,564 shares of the company’s stock worth $13,515,000 after purchasing an additional 1,005,850 shares during the period. Jasper Ridge Partners L.P. purchased a new stake in shares of Personalis in the 2nd quarter valued at approximately $193,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Personalis by 7,822.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 87,068 shares of the company’s stock valued at $1,167,000 after buying an additional 85,969 shares during the period. Bank of America Corp DE acquired a new stake in shares of Personalis during the 2nd quarter worth approximately $24,395,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Personalis during the 2nd quarter worth approximately $405,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.